Pershing Square's Bill Ackman said Valeant's tumble from above $250 a share to below $80 a share reminded him of Herbalife's surge in late 2013, which caused the stock to roughly double to about $80 a share.
Pershing Square's Bill Ackman said Valeant's tumble from above $250 a share to below $80 a share reminded him of Herbalife's surge in late 2013, which caused the stock to roughly double to about $80 a share.